NIR inspection of each tablet that exits a tablet press
In the pharmaceutical industry, waste represents at least 25% of the cost of quality. In 2004, the Food and Drug Administration (FDA) published a guide to promote the implementation of Process Analytical Technologies (PATs) in the pharmaceutical industry. This would allow better quality control (QC) and monitoring directly on the production line.
The FDA has encouraged manufacturers to use the PAT framework to develop and implement effective and efficient innovative approaches in pharmaceutical development, manufacturing and quality assurance, including continuous real-time quality assurance.
Typically, a limited number of tablets are randomly sampled within a batch for routine analysis. For a batch of a few million tablets, usually only between 10 and 30 are tested.2 The batch is then put in quarantine until QC results are obtained, which generates storage costs and reduces the company’s flexibility to respond to customer’s requirements. If the number of detected faulty tablets is higher than the Acceptance Quality Level, the batch will be manually sorted, reworked, or completely rejected and remanufactured – all of which lead to significant temporal and financial losses.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!